Last week’s unexpected CEO shuffle at for-profit health system Ardent Health was a “proactive, not reactive” move as the company’s board foresaw a need for strengthened core operating performance and margins amid the macroeconomic and policy headwinds of the coming years, Chief Financial Officer Alfred Lumsdaine said Wednesday.
The CFO, in a wide-ranging conversation at the Goldman Sachs 47th Annual Global Healthcare Conference, also sought to settle nerves around an early disclosure of softening volumes during the ongoing second quarter as a wide-ranging but manageable challenge.
The decision to share a sneak peek of the volumes, he said, was in service of the company’s reaffirmation of its 2026 adjusted EBITDA guidance ($485 million to $535 million) amid the leadership change.
“We are very comfortable and confident with our guidance as we go forward and for the rest of the year,” Lumsdaine said at the conference. “But yeah, we just thought we’d be remiss not to give a shape of what we’re seeing, and the fact with our reaffirmation of guidance that we’re continuing to work on the cost structure of the organization.”
On June 2, the publicly traded 30-hospital system shared the surprise announcement that, effective immediately, former CEO Marty Bonick was being replaced by Dave Caspers, who had served as its chief operating officer since March 2025.
The announcement broadly described the board’s view that Caspers would execute its operating and growth goals amid “a dynamic operating environment,” and thanked Bonick for his years leading the company through the COVID-19 pandemic and its 2024 initial public offering.
Lumsdaine underscored the board’s “extremely complimentary” farewell to Bonick, who he added helped Ardent from a hospital-centric organization to more of a health system and was “absolutely the right CEO for that business transformation.”
Meanwhile, Caspers, whose resume includes operating leadership at Walmart Health, Banner Health and Target, has spent his time at Ardent in the guts of its IMPACT (Improve Margins, Performance, Agility and Care Transformation) Program. The effort has so far exceeded its goal, leading Ardent during its last earnings call to increase the program’s estimated fiscal year 2026 savings from $40 million to $55 million.
“The expectation is there will be more of a premium on that underlying operational execution,” Lumdaine explained. “Dave was brought in to enhance our operations, strengthen our core operating platform, stand up and enhance out IMPACT Program. And, again, as the board looks at the next five years, … bringing that operational focus and rigor, and accelerating and enhancing our margin profile, takes primacy.”
Industry data suggest wide-ranging volume softness in Q2
As for the weakened volumes, Lumsdaine specified that the softer demand has been primarily among surgical cases and with more drop-offs on the inpatient side, “which we attribute to kind of the normal ongoing shift of procedures out of inpatient settings and to outpatient settings.”
Part of that characterization comes from industry information Ardent receives from revenue cycle management vendor Ensemble Health Partners, whose dataset is about 10 times the size of Ardent’s business—meaning that the trend does not appear to be limited to the health system alone.
“The data suggests very broad softening across, I would say, all geographies,” Lumsdaine said. “Not the same across all geographies, but across all geographies, as well as broad softness across payer type and service line.
“So that helps provide, we think, some of the underlying rationale to view the dynamics that underlie the softness,” he continued. “We think … overall macroeconomic concerns, inflationary pressures, etc. would certainly be one thesis when you see the breadth of the volume softness.”
Lumsdaine later touched on policy-related impacts on Ardent’s business, where he said the recently proposed rule of Medicaid work requirements “was really consistent with our expectations,” and, along with upcoming Medicaid cuts, underscores the company’s focus on margin improvement.
He also noted Ardent’s push to flesh out networks with a greater outpatient presence, where the company started with “only a handful of urgent care to now 46” and is similarly working on buffing up its ambulatory surgical center and freestanding EDs. Ardent’s historic capex spend of just under 3% revenue will exceed that barrier this year, “largely attributable to that de novo investment in ambulatory sites of care, and we could see it even get to the mid threes here in the next couple of years as that investment in our existing markets continue[s] to ramp,” he said.
Throughout, Lumsdaine acknowledged that Ardent hasn’t made as much headway as it anticipated on entering new markets through inorganic mergers and acquisitions, which he chalked up to a “transaction market that has not facilitated the types of transactions we are looking for.” Still, the company is on the lookout and has more than a billion dollars in capacity for such dealmaking, “should the right opportunity come along.”
“But the message I would want investors to be clear on is that will be done in an extremely disciplined way, and that we have so much opportunity to grow margins, to build out our existing market. Doing a bad deal—which could just be a good deal at a bad price—is still a bad deal. That’s our first order of business: to be very disciplined.”